Adjustment for oestrogen receptor status gave odds of a BRCA2 mutation carrier developing MF/MC breast cancer 4.2 times greater than a BRCA1 mutation carrier (CI: 2.12–8.19) (p < 0.001). This evidence concerns the gene BRCA1 and breast carcinoma.